je.st
news
Tag: merck
Merck KGaA to buy Sigma-Aldrich for $17 billion
2014-09-22 15:41:54| Biotech - Topix.net
That represents a 37 percent premium over the latest closing price of $102.37 on Sept. 19 and a 36 percent premium to the one-month average closing price, according to Merck.
German Merck to buy St. Louis-based Sigma-Aldrich
2014-09-22 14:32:56| Chemicals - Topix.net
German drug company Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion in a deal Merck says will strengthen its business in chemicals and laboratory equipment. Darmstadt-based Merck KGaA said Monday it is paying $140 per share in cash for all of Sigma-Aldrich's shares a premium of 37 percent over Friday's closing price of $102.37.
Tags: buy
german
merck
sigmaaldrich
Merck KGaA to Buy Sigma-Aldrich for to Add Chemicals
2014-09-22 14:32:55| Chemicals - Topix.net
Merck KGaA agreed to buy Sigma-Aldrich for $17 billion in cash to expand in chemicals used in research laboratories and medicines. Merck KGaA Executive Chairman Karl-Ludwig Kley and Sigma-Aldrich President and CEO Rakesh Sachdev speaks on "Bloomberg Surveillance."
Vet Students Benefit From Merck Animal Healths Commitment To The Profession
2014-09-18 20:34:46| Beef
It’s been a long-standing commitment by Merck Animal Health, and the large anima veterinary profession is better for it. In fact, during the past decade, Merck Animal Health has presented 87 outstanding bovine veterinary students with the American Association of Bovine Practitioners (AABP) Bovine Veterinary Student Recognition Award. read more
Tags: benefit
students
animal
commitment
Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
2014-09-17 15:31:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Omarigliptin significantly reduced HbA1c levels compared to placebo WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Mercks once-daily DPP-4 inhibitor JANUVIA (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Language: English Contact: MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (267) 305-1221 or +1 (310) 617-1067orInvestors:Justin Holko, +1 (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] next »